Menu
Search
|

Menu

Close
X

Genomic Health Inc GHDX.OQ (NASDAQ Stock Exchange Global Select Market)

76.20 USD
-2.69 (-3.41%)
As of Nov 16
chart
Previous Close 78.89
Open 78.90
Volume 249,975
3m Avg Volume 126,510
Today’s High 78.93
Today’s Low 75.57
52 Week High 91.03
52 Week Low 26.54
Shares Outstanding (mil) 36.12
Market Capitalization (mil) 2,814.00
Forward P/E 157.48
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
290
FY17
341
FY16
328
FY15
287
EPS (USD)
FY18
0.441
FY17
-0.113
FY16
-0.421
FY15
-1.030
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
157.48
29.34
Price to Sales (TTM)
vs sector
7.46
20.58
Price to Book (MRQ)
vs sector
11.10
4.23
Price to Cash Flow (TTM)
vs sector
90.25
21.19
Total Debt to Equity (MRQ)
vs sector
0.00
13.84
LT Debt to Equity (MRQ)
vs sector
0.00
9.93
Return on Investment (TTM)
vs sector
8.70
13.58
Return on Equity (TTM)
vs sector
8.86
15.11

EXECUTIVE LEADERSHIP

Kimberly Popovits
Chairman of the Board, President, Chief Executive Officer, Since 2012
Salary: $700,128.00
Bonus: $440,360.00
Gordon Cole
Chief Financial Officer, Chief Operating Officer, Since 2016
Salary: $530,400.00
Bonus: $203,870.00
Steven Shak
Chief Scientific Officer, Since 2014
Salary: $499,100.00
Bonus: $191,840.00
Phillip Febbo
Chief Medical Officer, Since 2013
Salary: --
Bonus: --
Laura Kammeyer
Chief Communications Officer, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

301 Penobscot Dr
REDWOOD CITY   CA   94063-4700

Phone: +1650.5569300

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

SPONSORED STORIES